Blueshift Asset Management LLC Takes $458,000 Position in Repligen Corporation (NASDAQ:RGEN)

Blueshift Asset Management LLC bought a new position in Repligen Corporation (NASDAQ:RGEN - Free Report) in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 3,598 shares of the biotechnology company's stock, valued at approximately $458,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Commerce Bank raised its holdings in shares of Repligen by 7.5% in the 1st quarter. Commerce Bank now owns 1,899 shares of the biotechnology company's stock worth $242,000 after buying an additional 133 shares in the last quarter. US Bancorp DE grew its position in Repligen by 4.0% in the first quarter. US Bancorp DE now owns 10,628 shares of the biotechnology company's stock valued at $1,352,000 after acquiring an additional 406 shares during the period. Nicolet Advisory Services LLC raised its stake in Repligen by 10.6% during the first quarter. Nicolet Advisory Services LLC now owns 3,607 shares of the biotechnology company's stock worth $459,000 after acquiring an additional 345 shares in the last quarter. Wealthquest Corp bought a new position in shares of Repligen during the first quarter valued at $264,000. Finally, Natixis Advisors LLC boosted its stake in shares of Repligen by 2.5% in the 1st quarter. Natixis Advisors LLC now owns 45,428 shares of the biotechnology company's stock valued at $5,780,000 after purchasing an additional 1,111 shares in the last quarter. 97.64% of the stock is owned by institutional investors.

Repligen Trading Up 1.6%

Shares of RGEN opened at $118.91 on Friday. The stock's fifty day simple moving average is $123.39 and its 200-day simple moving average is $136.49. The firm has a market capitalization of $6.68 billion, a PE ratio of -475.62, a price-to-earnings-growth ratio of 2.15 and a beta of 1.05. Repligen Corporation has a 12-month low of $102.96 and a 12-month high of $182.52. The company has a quick ratio of 5.79, a current ratio of 6.79 and a debt-to-equity ratio of 0.27.

Repligen (NASDAQ:RGEN - Get Free Report) last announced its quarterly earnings data on Tuesday, July 29th. The biotechnology company reported $0.37 earnings per share for the quarter, missing the consensus estimate of $0.40 by ($0.03). The firm had revenue of $182.37 million for the quarter, compared to the consensus estimate of $174.62 million. Repligen had a positive return on equity of 4.65% and a negative net margin of 2.05%. The business's revenue for the quarter was up 14.8% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.40 earnings per share. As a group, research analysts predict that Repligen Corporation will post 1.72 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on the stock. Royal Bank Of Canada increased their target price on shares of Repligen from $193.00 to $204.00 and gave the stock an "outperform" rating in a research report on Wednesday. HC Wainwright reaffirmed a "buy" rating and set a $180.00 price objective on shares of Repligen in a report on Monday, May 5th. Barclays assumed coverage on Repligen in a report on Tuesday, June 24th. They issued an "overweight" rating and a $150.00 target price on the stock. Canaccord Genuity Group dropped their price target on Repligen from $170.00 to $150.00 and set a "hold" rating for the company in a report on Wednesday, April 16th. Finally, Stephens upgraded Repligen to an "overweight" rating and set a $160.00 price objective for the company in a research report on Tuesday, July 22nd. Five equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat, Repligen currently has a consensus rating of "Moderate Buy" and a consensus target price of $169.45.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Corporation (NASDAQ:RGEN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.